Logo

Sema4: William Oh

Jan 14, 2021

Sema4 has appointed William Oh to the position of chief medical science officer, where he will drive strategy, scientific collaborations, clinical development, and adoption of the firm's technology.

Oh comes to Sema4 from Mount Sinai Health System, where he was chief of hematology and medical oncology and the deputy director of the Tisch Cancer Institute at the Icahn School of Medicine. He will continue to see patients at Mount Sinai.

Oh holds an MD from the New York University School of Medicine.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.